OGD2 Pharma

Cancer immunotherapy

Project Description

Develops and markets a monoclonal antibody specific to a form of the GD2 antigen (OAcGD2) for cancer immunotherapy

Does not have the serious side effects of anti-GD2 dinutuximab® (FDA approved 2015

Target of many pediatric cancers, brain cancers (gliomas), certain lung cancers, and certain breast cancers

Antibody drug candidate to regulatory development in 2016

Dr. Jean-Marc LE DOUSSAL
Founder & CEO

Immunologist and serial entrepreneur with over 20 years experience in the creation and development of startup

Project Details

Back to Top